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Abstract
Objective: Bone metastases in gastrointestinal (GI) malignancies are uncommon and known to be predominantly 
lytic thus rendering a limited role for conventional bone scintigraphy. The aim of the study is to review Tc99m MDP 
bone scans performed in patients with known GI malignancy and the utility of Single-photon emission computed 
tomography (SPECT)/CT in characterization of bone lesions.
Methods: Retrospective review of bone scans was done from June 2014 to December 2016 in patients with known GI 
malignancy, using electronic Hospital Information System.
Results: A total of 110 patients (60 males, 50 females; Age range: 22–84 years, Mean Age 51.4 years with SD 
of 14.8) had bone scan over a period of 30 months. The commonest indications for referral were suspected bone 
metastasis on other imaging modalities including [CT (n = 56), Magnetic resonance imaging (n = 10), Positron 
emission tomography/CT (n = 6)], musculoskeletal pain (n = 37), pathological fracture (n = 1), neurological symptoms 
(n = 1), hypercalcemia (n = 1) and others (n =14) including restaging workup etc. Metastatic lesions were identified in 
32 (29%) patients whereas 78 (71%) patients had benign non-aggressive lesions leading to normal bone scans. Among 
32 patients with osseous metastasis, 8 (25%) patients had unifocal lesion; axial skeleton (n = 2) appendicular skeleton 
(n = 6), 24 (75%) patients had multifocal lesions; axial skeleton (n = 6), appendicular skeleton (n = 6) and both axial 
+ appendicular (n = 12). Four (12%) patients had concurrent visceral metastases. In our cohort, based on the location 
of primary tumour, the frequencies of osseous metastasis were; esophagus = 15 out of 43 (35%), gastric = 7 out of 
18 (39 %), gastro-esophageal junction = 1 out of 8 (1.5%) and colorectal = 9 out of 40 (22.5). SPECT/CT was acquired 
in 29 out of 110 patients, which characterized metastatic lesions (n = 12) and benign looking non-aggressive entities 
(n =17). Overall, bone scan upstaged disease in 31% and down staged 15% patients.
Conclusion: Bone metastases in GI malignancies, though uncommon, show an aggressive pattern, with axial and 
appendicular involvement, and can be readily identified with hybrid bone scintigraphy in symptomatic patients.
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 Introduction
Cancer was established to be the second leading cause of 
mortality in 2015. The incidence of cancer is expected 
to incline in future on the basis of epidemiological 
transitions. Therefore, we are at imminent need for 
early cancer diagnosis and early treatment along with 
preventive methods to decrease the rate of death in 
upcoming years.[1]
Gastrointestinal (GI) tract malignancies are one of 
the most incident cancers. However, the incidence 
of skeletal metastases in GI tumour is not very high. 
Once the cancer spread to the bones, it has significant 
implication and impact on patient management, outcome 
and prognosis. The reported incidence of skeletal 
metastases from GI tumours ranges from 3% to 5%.[2] 
JOURNAL OF CANCER & ALLIED SPECIALTIES 2
ORIGINAL ARTICLE J Cancer Allied Spec 2018;4(1):3
Bone metastasis increases the morbidity and alters the 
quality of life. Life events related to bone metastasis 
are referred to as skeletal-related events (SREs). 
SREs include bone pains, spinal-cord compression, 
pathological fractures and hypercalcemia etc.[2] 
Pathological fractures due to metastatic skeletal disease 
increases the risk of death.
Therefore utmost goal of therapy in disseminated 
malignancies is to prevent pathological fractures.[3]
Regarding treatment, the aim is always to prevent SREs 
and multimodality comes into play at this stage. Targeted 
local radiotherapeutics can be used for limited bone 
disease or localized skeletal metastasis. However, in 
multifocal metastatic cases chemotherapy or hormonal 
therapies are of benefit.[4]
Primary presentation of many GI tumours can be bony 
metastases without prior GI symptoms. It is rare and 
infrequently reported in the recent literature.[5]
Therefore morbidity related to SREs needs to be promptly 
addressed to detour the devastating results of bone 
metastases.[6]
In the current guidelines, no screening investigation is 
in practice to evaluate the bone metastasis exclusively 
at baseline staging work up. Bone metastases in GI 
malignancies are predominantly osteolytic, thus rendering a 
limited role for conventional bone scintigraphy. Therefore, 
bone scintigraphy is done for specific clinical indication 
or for suspicion of bone metastases raised on imaging.[2]
Single-photon emission computed tomography (SPECT)/
CT in addition to bone scintigraphy increases the diagnostic 
performance and accuracy in terms of cancers staging.[7]
Purpose
The aim of this study is to review Tc99m MDP bone scans 
performed in patients with known GI malignancy and the 
utility of SPECT/CT to characterize the bone lesions.
Methods
Electronic medical records of 110 consecutive patients 
with GI malignancies were reviewed. Retrospective 
review of bone scans was done using electronic 
Hospital Information System, acquired between June 
2014 and December 2016. All patients underwent Tc-
99m MDP bone scan with dosage according to weight 
based criteria. Where suspicious, the osseous uptake 
on Tc-99m MDP bone scan was further correlated with 
additional radiological imaging or SPECT/CT in a few 
cases.
The association of bone metastases with gender and age 
was evaluated. Furthermore lesions were evaluated for 
uni or multifocality.
Finally, the change in the stage of the tumour was assessed 
on the basis of bone scan results.
Results
A total of 110 patients (60 males, 50 females; age range: 
22–84 years) had bone scan over a 30 months period. 
Figure 1: Characterization of skeletal lesions 
Figure 2: Distribution of skeletal metastases in axial and 
appendicular skeleton
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The common indications for referral were suspected 
bone metastasis on other imaging modalities including 
[CT (n = 56), Magnetic resonance imaging (MRI) 
(n = 10), Positron emission tomography (PET)/CT (n = 6)], 
musculoskeletal pain (n = 37), pathological fracture (n = 1), 
neurological symptoms (n = 1), hypercalcemia (n = 1) or 
others (n = 14). Metastatic lesions were identified in 32 (29%) 
patients while 78 (71%) patients had benign, non-aggressive 
lesions or normal bone scan as shown in the Figure 1.
Among 32 patients with osseous metastases, unifocal lesion 
(25%) was identified in 8 patients: Axial skeleton (n = 2) 
appendicular skeleton (n = 6). 24 out of these 32 (75%) 
patients, had multifocal lesions; axial skeleton (n = 6), 
appendicular skeleton (n = 6) and both axial + appendicular 
(n = 12) as shown in the Figure 2. Only 4 (12%) patients 
had concurrent visceral metastases. In our cohort, based on 
the location of primary tumour, the frequencies of osseous 
metastases were; oesophagus 35% (15 out of 43), gastric 
39 % (7 out of 18), gastroesophageal junction 1.5% (1 out 
of 8) and colorectal 22.5% (9 out of 40).
SPECT/CT was acquired in 29 out of 110 patients, which 
characterized metastatic lesions (n = 12) and benign 
looking non-aggressive entities (n = 17). As it is an 
established fact that SPECT/CT increases the specificity 
of bone scan [Figures 3-5].
Overall, bone scan upstaged disease in 31% (n = 34) and 
down staged the disease in 15% (n = 17) patients.
Figure 3: 62-year-old male with Squamous cell carcinoma 
esophagus, on follow-up computed tomography suspicion of 
metastases was raised, Bone Scan showed multiple lesions and 
upgraded the stage by involvement of left femoral neck lytic lesion
Figure 4: 74-year-male with squamous cell carcinoma esophagus, 
status/post radiation therapy. Patient developed backache and 
underwent bone scan. Scan showed metastases Single-photon 
emission computed tomography/computed tomography shows 
underlying compression fracture of T-10, T-12
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Discussion
Indication for bone scans
In routine no radiological imaging is done exclusively to 
look for bone metastases in patients with GI malignancy. 
This is due to very low incidence of bone metastasis in 
these patients.[2,3,7,8] Portales et al. reported incidence of 
3–5% therefore, there has to be a very specific indication 
to order a bone scan.[2]
In our data, the major indication for referral was an 
indeterminate lesion on other radiological imaging that 
was done for routine staging or follow up re-staging. 
In 51% cases, the referral for bone scintigraphy was 
from suspicious lesion on CT scan followed by 9% from 
MRI and 5% from PET/CT scan. Other than anatomical 
suspicious lesions there have been multiple clinical 
symptoms and findings leading to evaluation of skeletal 
metastatic involvement. In our data major clinical 
symptom included musculoskeletal pain in 34% cases. 
Other findings included pathological fracture, neurological 
symptoms and hypercalcemia. 
Portales et al. described these clinical findings as SREs. 
In the study SREs occurred in 53.6% of patients. Similar 
to our results, they observed (77.2%) bone pain being the 
most frequent clinical sign leading to diagnosis of bone 
metastases followed by (5.8%) neurological signs.[2] Other 
symptoms including hypercalcemia and pathological 
fractures remained uncommon in both studies.
Our study showed Metastatic lesions in 32 (29%) 
patients while 78 (71%) patients had benign non-
aggressive lesions or normal bone scans. In comparison, 
Portales et al. reported bone metastases on bone scan in 
189 patients (5.5%). Amongst these patients, 173 (91.5%) 
patient’s bone metastases were diagnosed by bone 
scintigraphy.[2]
This difference may be explained on the basis of selection 
bias, since our study was a retrospective analysis of bone 
scans acquired in GI malignancies. Portales et al. selected 
the patients of GI malignancies who developed bone 
metastases.
Extent of skeletal disease
In our data amongst 32 patients with osseous metastasis 
unifocal lesion (25%) were identified in 8 patients. 
24 (75%) patient had multifocal lesions.
4 (12%) patients had concurrent visceral metastasis 
along with osseous metastasis. Which means exclusive 
bone metastases was identified in 28 (88%) patients. 
This highlights even with a small percentage of patients 
developing bone metastases, it has great clinical impact. 
Metastatic skeletal disease appears more aggressive and 
multifocality is not uncommon. We report more frequent 
involvement of appendicular skeleton as compared to axial 
skeleton. In contrast Kanthan et al.[9] showed metastases in 
axial skeleton in 65% of patients and 35% in appendicular 
skeleton metastases.[6]
Figure 5: 50-year-old male with Squamous cell carcinoma of esophagus underwent bone scintigraphy due to hypercalcemia [ionized 
calcium=1.95 (Normal range 1.09–1.3)]. On Single-photon emission computed tomography/computed tomography images, there 
was cortical thinning in the lower part of right femoral shaft. No anatomical abnormality was identified in left femoral shaft. These 
sites were labelled as metastatic involved sites. However Serum magnesium, phosphorus and parathyroid hormone were within 
normal limits
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Role of hybrid imaging
In developing era of hybrid imaging, the role of radiological 
imaging plays a pivot role in lesion characterization. As 
demonstrated in our study, SPECT/CT was acquired in 29 
out of 110 patients, which characterized metastatic lesions 
(n = 12) and benign looking non-aggressive entities (n = 17).
Overall, bone scan upstaged disease in 31% and down staged 
15% patients. Guezennec et al. showed 91 equivocal uptakes 
on whole body scans which were further characterized on 
SPECT/CT. Note was made of 71.4% benign findings and 
14.3% suspicious findings and 14.3% remained equivocal 
even after SPECT/CT. Therefore they down staged 73.6% 
and upstaged 15.1% amongst their equivocal results.[7]
Aggressiveness of skeletal disease
There are random reports in literature which state the 
appearance of bone metastases preceding the diagnosis of 
GI malignancies and absence of GI related symptoms.[5] In 
this scenario, the evaluation of skeletal metastasis becomes 
more crucial and needs to be done in timely manner.
The sequelae of skeletal metastases, particularly 
pathologic fractures are reported to affect the overall 
survival of patient with skeletal metastatic diseases.[3]
To summarize, bone scanning as a part of staging workup is a 
very helpful tool in identifying patients with bone metastases. 
This finding has a great impact in clinical decision making 
between local control of unifocal metastases versus palliation 
for multifocal disease. Bone scintigraphy is not meant to be 
done in all cases of GI malignancies, but needs to be done 
as early as possible in patients with symptoms.
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